MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
P/B ratio for MERCK Kommanditgesellschaft auf Aktien (MRK.DE)
P/B ratio as of 2023: 2.35
According to MERCK Kommanditgesellschaft auf Aktien's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.35. At the end of 2022 the company had a P/B ratio of 3.03.
P/B ratio history for MERCK Kommanditgesellschaft auf Aktien from 2002 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.35 |
| 2022 | 3.03 |
| 2021 | 4.63 |
| 2020 | 3.60 |
| 2019 | 2.56 |
| 2018 | 2.28 |
| 2017 | 2.79 |
| 2016 | 3.08 |
| 2015 | 3.05 |
| 2014 | 2.91 |
| 2013 | 2.57 |
| 2012 | 2.13 |
| 2011 | 1.60 |
| 2010 | 1.26 |
| 2009 | 1.50 |
| 2008 | 1.48 |
| 2007 | 2.19 |
| 2006 | 4.07 |
| 2005 | 4.13 |
| 2004 | 3.36 |
| 2003 | 2.56 |
| 2002 | 2.17 |